BioCentury | May 17, 2018
Finance

Europe’s piece of the pie

...startup Junction Therapeutics Ltd., launched in 2016, has the siRNA candidate JT-02 targeting CLDN5 and OCLN...
...Israel Targets CLDN5 - Claudin 5 DYRK1A - Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A OCLN - Occludin...
BioCentury | Apr 17, 2018
Distillery Techniques

Disease models; drug properties

...express high levels of mRNA for cytochrome P450 3A4 (CYP3A4), the tight junction protein occludin (OCLN...
...Walters Nagoya City University ATP-binding cassette sub-family B member 1 (ABCB1) (MDR1) (PGP) (CD243) Cytochrome P450 3A4 (CYP3A4) Occludin (OCLN...
BioCentury | Aug 16, 2017
Distillery Techniques

Disease models

...exhibited BBB features, including high expression of tight junction proteins claudin 5 (CLDN5) and occludin (OCLN...
...Tuzman Brigham and Women's Hospital ATP-binding cassette sub-family B member 1 (ABCB1) (MDR1) (PGP) (CD243) Claudin 5 (CLDN5) Occludin (OCLN...
BioCentury | Jul 26, 2017
Emerging Company Profile

Breaching the gates

...a mouse model of cerebral edema. The second program, JT-02, combines siRNA against CLDN5 and OCLN...
...NYSE:MRK), Kenilworth, N.J. Trinity College Dublin, Dublin, Ireland Targets CLDN5 - Claudin 5 OCLN -- Occludin...
...amyloid-β across the blood-brain barrier.” Science Advances (2015) Stephen Hansen, Associate Editor Junction Therapeutics Ltd. Claudin 5 (CLDN5) Occludin (OCLN) Alzheimer's...
BioCentury | Dec 3, 2015
Translation in Brief

IL-17A's autoimmune dichotomy

...that in cells from models pretreated with an anti-IL-17A antibody, the tight junction protein occludin (OCLN...
BioCentury | Oct 8, 2015
Translation in Brief

Holey BBB

...team, led by Matthew Campbell, used siRNAs to simultaneously knockdown claudin 5 (CLDN5) and occludin (OCLN...
...research assistant professor of genetics at Trinity College. Additionally, mouse models treated with CLDN5 and OCLN...
...good safety profile" in mice and monkeys because they are highly specific for CLDN5 and OCLN...
BioCentury | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Claudin 5 (CLDN5); occludin (OCLN); β amyloid (Aβ)

...and OCLN could help treat AD. In endothelial cell cultures, knockdown of both CLDN5 and OCLN...
...expression of the proteins. In a transgenic mouse model of AD, knockdown of CLDN5 and OCLN...
...combination with antibodies against Aβ in the mouse model. TARGET/MARKER/PATHWAY: Claudin 5 (CLDN5) ; occludin (OCLN...
BioCentury | Sep 5, 2013
Distillery Techniques

Technology: Disease models

...help evaluate antiviral drug candidates. Transgenic mice with stable expression of human CD81 and occludin (OCLN...
...available to the research community. SciBX 6(34); doi:10.1038/scibx.2013.941 Published online Sept. 5, 2013 Use of OCLN...
BioCentury | Jun 16, 2011
Distillery Techniques

Technology: Disease models

...of human CD81, scavenger receptor class B member 1 (SCARB1), claudin 1 (CLDN1) and occludin (OCLN...
...compared with no immunization. Next steps include testing transgenic mice with only human CD81 and OCLN...
BioCentury | Jun 16, 2011
Cover Story

HCV's mighty mouse

...CD81 , scavenger receptor class B member 1 (SCARB1) , claudin 1 (CLDN1) and/or occludin (OCLN...
...OCLN) to mice. About 18%-25% of murine hepatocytes had strong expression of human CD81 and OCLN...
...particles. HCV infection took place in about 5% of murine hepatocytes expressing human CD81 and OCLN...
Items per page:
1 - 10 of 13